{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:55:31Z","timestamp":1793166931167,"version":"4.5.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Parkinson\u2019s disease (PD)-related constipation may affects both disease occurrence and disease progression. Probiotics, as a potential therapeutic intervention, have attracted the attention of researchers, but the evidence of their efficacy and safety has not been systematically reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>A systematic review and meta-analysis of randomized controlled trials of probiotics in the treatment of PD constipation was conducted to determine the efficacy and safety of probiotics in the treatment of PD constipation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four databases (The Cochrane Central Register of Controlled Trials, Embase, PubMed, and Web of Science) were searched from their establishment to June 1, 2022. We included randomized controlled trials of probiotics for the treatment of constipation in patients with PD, with probiotics in the experimental group and a placebo, another treatment, or no treatment in the control group. The primary outcome was the number of bowel movements per week. Secondary outcomes included nonmotor symptoms (NMS), gut transit time (GTT), abdominal pain, abdominal distention, constipation, and quality of life scores. Stata15.1 was used to generate a summary of the data and perform a descriptive analysis if necessary. The GRADE tool was used to assess the quality of the evidence and the Cochrane guidelines to assess the risk of bias for each study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Finally, four qualified RCTs were included, comprising 287 participants. Compared with the control group, probiotics could effectively increase the frequency of defecation per week in PD patients (WMD = 1.02. 95%CI: 0.56\u20131.48, and <jats:italic>P<\/jats:italic> &amp;lt; 0.00001), but the heterogeneity was high, and the quality of the evidence was low. There was no significant difference in average stool consistency between patients with PD treated with probiotics and those given a placebo in (WMD = \u20130.08. 95%CI: \u20131.42\u20131.26, and <jats:italic>P<\/jats:italic> = 0.908). In addition, the results suggested that probiotics have no obvious effect on additional indicators of gastrointestinal dysfunction, such as GTT, abdominal pain, and abdominal distension, and there is insufficient evidence on their ability to improve NMS and Parkinson\u2019s disease Questionnaire 39 summary indices (PDQ39-SI). Safety issues should be carefully explained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is insufficient evidence supporting the use of probiotics to treat constipation in patients with PD. Taking all the results together, probiotics have potential value in the treatment of PD-related constipation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO CRD42022331325.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.1038928","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:00:20Z","timestamp":1668060020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Probiotics for constipation in Parkinson\u2019s: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Shao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengya","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1212\/wnl.57.3.456","article-title":"Frequency of bowel movements and the future risk of parkinson's disease","volume":"57","author":"Abbott","year":"2001","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00427-6","article-title":"Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in parkinson's disease","volume":"16","author":"Aho","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"B3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/mds.870120617","article-title":"Constipation in parkinson's disease: objective assessment and response to psyllium","volume":"12","author":"Ashraf","year":"1997","journal-title":"Mov Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/nutrit\/nuz080","article-title":"Probiotics and prebiotics: focus on psychiatric disorders - a systematic review","volume":"78","author":"Barbosa","year":"2020","journal-title":"Nutr. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/wnl.0000000000003127","article-title":"Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT","volume":"87","author":"Barichella","year":"2016","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0408-2","article-title":"Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with parkinson's disease","volume":"5","author":"Barrenschee","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2021.105640","article-title":"The gut microbiota-brain axis, psychobiotics and its influence on brain and behaviour: A systematic review","volume":"137","author":"Barrio","year":"2022","journal-title":"Psychoneuroendocrinology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1017\/s1092852900013560","article-title":"Non-motor aspects of parkinson's disease","volume":"11","author":"Borek","year":"2006","journal-title":"CNS Spectr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J. Neural Transm (Vienna)"},{"key":"B10","first-page":"117","article-title":"Use of probiotics for the treatment of constipation in parkinson's disease patients","volume":"57","author":"Cassani","year":"2011","journal-title":"Minerva Gastroenterol. Dietol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s1474-4422(09)70068-7","article-title":"Non-motor symptoms of parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11910-011-0204-0","article-title":"Gastrointestinal features of parkinson's disease","volume":"11","author":"Cloud","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"Cd002115","DOI":"10.1002\/14651858.CD002115.pub5","article-title":"Management of faecal incontinence and constipation in adults with central neurological diseases","author":"Coggrave","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"Cd002115","DOI":"10.1002\/14651858.CD002115.pub3","article-title":"Management of faecal incontinence and constipation in adults with central neurological diseases","author":"Coggrave","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.879491","article-title":"A systematic review on the effects of different types of probiotics in animal alzheimer's disease studies","volume":"13","author":"de Rijke","year":"2022","journal-title":"Front. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3945\/an.116.014407","article-title":"Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation","volume":"8","author":"Dimidi","year":"2017","journal-title":"Adv. Nutr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/mds.870080115","article-title":"Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study","volume":"8","author":"Edwards","year":"1993","journal-title":"Mov Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/s1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in parkinson's disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.871710","article-title":"Exploring the causal effect of constipation on parkinson's disease through mediation analysis of microbial data","volume":"12","author":"Fu","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/aje\/kwr119","article-title":"A prospective study of bowel movement frequency and risk of parkinson's disease","volume":"174","author":"Gao","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/cia.S106284","article-title":"Nonmotor gastrointestinal disorders in older patients with parkinson's disease: Is there hope","volume":"11","author":"Georgescu","year":"2016","journal-title":"Clin. Interv Aging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054129","article-title":"Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD)","volume":"12","author":"Hatano","year":"2022","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","article-title":"Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats","volume":"128","author":"Holmqvist","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244680","article-title":"Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in parkinson's disease: A randomised controlled trial","volume":"15","author":"Ibrahim","year":"2020","journal-title":"PLos One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-0404.2007.00900.x","article-title":"Clinical aspects of bowel symptoms in parkinson's disease","volume":"117","author":"Krogh","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"B28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/nutrit\/nuaa037","article-title":"Probiotics for dementia: a systematic review and meta-analysis of randomized controlled trials","volume":"79","author":"Kr\u00fcger","year":"2021","journal-title":"Nutr. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2021.07.026","article-title":"Neurogenic and anti-inflammatory effects of probiotics in parkinson's disease: A systematic review of preclinical and clinical evidence","volume":"98","author":"Leta","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.757673","article-title":"Effect of probiotic supplementation on cognitive function and metabolic status in mild cognitive impairment and alzheimer's disease: A meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front. Nutr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/mds.23368","article-title":"Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with parkinson's disease","volume":"25","author":"Li","year":"2010","journal-title":"Mov Disord."},{"key":"B32","first-page":"S308","article-title":"The impact and management of nonmotor symptoms of parkinson's disease","author":"Lyons","year":"2011","journal-title":"Am. J. Manag Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/nu14010020","article-title":"Probiotics for alzheimer's disease: A systematic review","volume":"14","author":"Naomi","year":"2021","journal-title":"Nutrients"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2174\/1567205019666220318092003","article-title":"Effects of supplementation with probiotics in experimental models of alzheimer's disease: A systematic review of animal experiments","volume":"19","author":"Neta","year":"2022","journal-title":"Curr. Alzheimer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1517\/14728214.2013.766168","article-title":"Emerging drugs for autonomic dysfunction in parkinson's disease","volume":"18","author":"Perez-Lloret","year":"2013","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.coph.2008.07.008","article-title":"Pharmacologic treatment of constipation: what is new","volume":"8","author":"Pohl","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6762528","article-title":"Gastrointestinal dysfunctions in parkinson's disease: Symptoms and treatments","volume":"2016","author":"Poirier","year":"2016","journal-title":"Parkinsons Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1136\/jnnp.74.2.268","article-title":"Colonic transit time and rectoanal videomanometry in parkinson's disease","volume":"74","author":"Sakakibara","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e3181c34af5","article-title":"Medical records documentation of constipation preceding Parkinson disease: A case-control study","volume":"73","author":"Savica","year":"2009","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/bs.irn.2017.06.003","article-title":"Constipation in parkinson's disease","volume":"134","author":"Stocchi","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-019-0439-x","article-title":"The pros, cons, and many unknowns of probiotics","volume":"25","author":"Suez","year":"2019","journal-title":"Nat. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1212\/wnl.0000000000010998","article-title":"Probiotics for constipation in Parkinson disease: A randomized placebo-controlled study","volume":"96","author":"Tan","year":"2021","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2147\/cia.S139163","article-title":"Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review","volume":"13","author":"Ticinesi","year":"2018","journal-title":"Clin. Interv Aging"},{"key":"B44","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41575-020-0339-z","article-title":"Parkinson Disease and the gut: New insights into pathogenesis and clinical relevance","volume":"17","author":"Travagli","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","article-title":"Short chain fatty acids and gut microbiota differ between patients with parkinson's disease and age-matched controls","volume":"32","author":"Unger","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1212\/01.wnl.0000266593.50534.e8","article-title":"Patient-reported autonomic symptoms in Parkinson disease","volume":"69","author":"Verbaan","year":"2007","journal-title":"Neurology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.730036","article-title":"Efficacy and safety of probiotics for the treatment of alzheimer's disease, mild cognitive impairment, and parkinson's disease: A systematic review and meta-analysis","volume":"14","author":"Xiang","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1016\/j.clnu.2020.01.005","article-title":"Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults","volume":"39","author":"Zhang","year":"2020","journal-title":"Clin. Nutr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3390\/foods10071672","article-title":"Probiotics for mild cognitive impairment and alzheimer's disease: A systematic review and meta-analysis","volume":"10","author":"Zhu","year":"2021","journal-title":"Foods"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1038928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:00:25Z","timestamp":1668060025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1038928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":49,"alternative-id":["10.3389\/fcimb.2022.1038928"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1038928","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"article-number":"1038928"}}